Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Cancer. 2014 Nov 6;121(5):774–782. doi: 10.1002/cncr.29121

Table 1. Demographic and Treatment Characteristics of Survivors Exposed to CNS-Directed Therapy (N= 1304).

Mean SD
Age at Evaluation (years) 31.6 7.9
Age at Diagnosis (years) 7.5 5.0

N %*

Age at Evaluation (years)
 18-30 637 48.8
 31-40 472 36.2
 >40 195 15.0
Age at Diagnosis (years)
 0-4 486 37.3
 5-9 368 28.2
 10-14 306 23.5
 ≥15 144 11.0
Time since Diagnosis (years)
 10-19 439 33.7
 ≥20 865 66.3
Gender
 Male 654 50.2
 Female 650 49.8
Ethnicity
 Caucasian 1145 87.8
 Other 159 12.2
Education
 ≤Some college 790 62.5
 ≥College 474 37.5
Marital Status
 Single, never married 488 38.6
 Married, living as married 601 47.6
 Divorced, no longer living as married 175 13.8
Living Arrangement**
 Dependent 390 29.9
 Independent 914 70.1
Household Income
 <$40,000 520 47.2
 ≥$40,000 582 52.8
Health Insurance
 Yes 996 76.7
 No 302 23.3
Dental Insurance
 Yes 696 55.8
 No 552 44.2
Diagnosis+
 Leukemia 872 66.9
 Lymphoma 129 9.9
 CNS Tumor 142 10.9
 Embryonal 26 2.0
 Bone and Soft Tissue Sarcoma 111 8.5
 Other 24 1.8
Radiation+
 Chest 212 16.3
 Cranial (CRT) 674 51.7
Chemotherapy+
 Anthracyclines 825 63.3
 Alkylating Agents 860 66.0
 Antimetabolites 990 75.9
 Anti-Tumor Agents 67 5.1
 Corticosteriods 952 73.0
 Platinum 122 9.4
CNS Directed Therapy+
 HD/IV/IT/IO MTX 1036 79.5
 HD Ara-C‡‡ 105 8.1
 HD/IV/IT/IO MTX and HD Cytarabine 1057 81.1
 HD/IV/IT/IO MTX and CRT 1196 91.2
 HD Ara-C and CRT 725 55.6
 HD/IV/IT/IO MTX, HD Ara-C and CRT 1199 92.0
*

Percentages based on participants with available data

**

independent living (living alone, with a spouse/roommate or as a caretaker); dependent living (living with parents/family)

+

variable not included in multivariable models

high dose/intravenous/intrathecal/intra-ommaya methotrexate

‡‡

high dose cytarabine

HHS Vulnerability Disclosure